SCHEMBL714065

SCHEMBL714065

O=S(=O)(Nc1nccs1)c1ccc(Nc2nc(-c3ccccc3)c(-c3ccccc3)s2)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.64
KMT2A Q03164 5/20 0.64
POLB P06746 2/20 0.64
TDP1 Q9NUW8 3/20 0.55
RECQL P46063 2/20 0.55
KDM4E B2RXH2 2/20 0.55
USP2 O75604 1/20 0.55
PPARG P37231 1/20 0.55
BLM P54132 1/20 0.55
NCOA2 Q15596 1/20 0.55
NCOA1 Q15788 1/20 0.55
EGFR P00533 1/20 0.54
KDR P35968 1/20 0.54
ALDH1A1 P00352 4/20 0.52
PKM P14618 3/20 0.52
ATM Q13315 1/20 0.52
SCN3A Q9NY46 2/20 0.52
SCN1A P35498 2/20 0.52
SCN5A Q14524 2/20 0.52
SCN9A Q15858 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL712318 0.81 MEN1 (0.63) MEN1KMT2APOLBTDP1RECQL
SCHEMBL713887 0.79 ILK (0.65) MEN1KMT2APOLBTDP1RECQL
SCHEMBL4110122 0.79 KDM1A (0.76) MEN1KMT2AKDM4EALDH1A1PKM
SCHEMBL711139 0.78 MEN1 (1.00) MEN1KMT2APOLBTDP1RECQL
SCHEMBL712071 0.77 MEN1 (0.58) MEN1KMT2APOLBTDP1KDM4E
SCHEMBL712189 0.76 SCN3A (0.50) MEN1KMT2APOLBEGFRKDR
SCHEMBL326633 0.76 ALDH1A1 (0.71) MEN1KMT2ATDP1KDM4EALDH1A1
SCHEMBL8056906 0.76 KDM1A (0.76) MEN1KMT2AKDM1APTGS1HTT
SCHEMBL713988 0.75 ALDH1A1 (0.64) MEN1KMT2APOLBTDP1KDM4E
Hydrochloric Acid SCHEMBL27575105 0.75 ALDH1A1 (0.69) MEN1KMT2ATDP1KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8124610-B2 Sodium channel inhibitors ICAGEN INC. (US) 2012-02-28 US claimed
US-8124610-B2 Sodium channel inhibitors ICAGEN INC. (US) 2012-02-28 US disclosed
EP-2173743-A2 SODIUM CHANNEL INHIBITORS Icagen, Inc. (US) 2010-04-14 EP disclosed
US-20090023740-A1 SODIUM CHANNEL INHIBITORS ICAGEN (US) 2009-01-22 US disclosed
WO-2009012242-A2 SODIUM CHANNEL INHIBITORS ICAGEN, INC. (US) 2009-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023740-A1 SODIUM CHANNEL INHIBITORS TRPV1, SCN1A, SCN2A MEN1 4426/4885KMT2A 1945/4885POLB 4439/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.